Skip to main content
Premium Trial:

Request an Annual Quote

Cellectricon, StressMarq Ink Neurodegenerative Disease Research Deal

NEW YORK — Cellectricon said on Tuesday that it has signed an agreement to use StressMarq Biosciences' reagents for its neurodegenerative research.

Mölndal, Sweden-based Cellectricon provides drug discovery services, with a focus on chronic pain and neurodegenerative disease. Among its areas of research is the spread of neurodegenerative disease-associated peptides, such as amyloid-beta peptides, tau, and alpha-synuclein, that characterizes Alzheimer's disease and Parkinson's disease.

Under the terms of the deal, British Columbia-based StressMarq will provide Cellectricon access to certain of its life science reagents including pre-formed fibrils of tau and alpha-synuclein, which can initiate protein aggregation and induce disease pathology in vitro and in vivo. Additional terms were not disclosed.

"A vital factor for enabling in vitro modelling of neuropathological processes is access to well-characterized reagents such as seed competent fibrils and filaments," Sebastian Illes, Cellectricon's director of central nervous system research, said in a statement. "Our collaboration with StressMarq … will enable us to access their high-quality portfolio of reagents for our services."

The Scan

More Boosters for US

Following US Food and Drug Administration authorization, the Centers for Disease Control and Prevention has endorsed booster doses of the Moderna and Johnson & Johnson SARS-CoV-2 vaccines, the Washington Post writes.

From a Pig

A genetically modified pig kidney was transplanted into a human without triggering an immune response, Reuters reports.

For Privacy's Sake

Wired reports that more US states are passing genetic privacy laws.

Science Paper on How Poaching Drove Evolution in African Elephants

In Science this week: poaching has led to the rapid evolution of tuskless African elephants.